Aura Biosciences (Aura Biosciences) Debt-to-Asset : 0.08 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Aura Biosciences Debt-to-Asset?

Aura Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $2.74 Mil. Aura Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $16.58 Mil. Aura Biosciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $235.03 Mil. Aura Biosciences's debt to asset for the quarter that ended in Mar. 2024 was 0.08.

Aura Biosciences Debt-to-Asset Historical Data

The historical data trend for Aura Biosciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aura Biosciences Debt-to-Asset Chart

Aura Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

0.01

0.09

0.08

Aura Biosciences Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial												0.10	0.11	0.11	0.08	0.08

Competitive Comparison of Aura Biosciences's Debt-to-Asset

For the Biotechnology subindustry, Aura Biosciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aura Biosciences's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aura Biosciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Aura Biosciences's Debt-to-Asset falls into.

Aura Biosciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Aura Biosciences's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.687	+	16.87)	/	255.075
	=	0.08

Aura Biosciences's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.741	+	16.579)	/	235.025
	=	0.08

Aura Biosciences (NAS:AURA) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Aura Biosciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Aura Biosciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Aura Biosciences (Aura Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aura Biosciences Inc (NAS:AURA) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

85 Bolton Street, Cambridge, MA, USA, 02140

Website

https://www.aurabiosciences.com

Aura Biosciences Inc is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system to create long-lasting anti-tumor immunity.

Executives

Matrix Capital Management Company, Lp	10 percent owner	1000 WINTER STREET, C/O MATRIX CAPITAL MANAGEMENT, WALTHAM MA 02451
David Michael Johnson	director	C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Julie B Feder	officer: Chief Financial Officer	C/O VERASTEM, INC., 117 KENDRICK STREET, SUITE 500, NEEDHAM MA 02494
De Los Pinos Elisabet	director, officer: Chief Executive Officer	C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Janet Jill Hopkins	officer: See Remarks	C/O AURA BIOSCIENCES, INC., 80 GUEST STREET, BOSTON MA 01235
Cadmus Rich	officer: See Remarks	C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Rosch Mark De	officer: Chief Operating Officer	C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Medicxi Ventures Management (jersey) Ltd	10 percent owner	C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
Medicxi Growth I Lp	10 percent owner	C/O ELIAN FUND SERVICES (JERSEY) LIMITED, 44 ESPLANADE, ST HELIER Y9 JE4 9WG
Giovanni Mariggi	director	C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Medicxi Growth I Gp Ltd	10 percent owner	C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
Medicxi Growth Co-invest I Lp	10 percent owner	C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
David E. Goel	10 percent owner	C/O MATRIX CAPITAL MANAGEMENT CO., LP, 1000 WINTER STREET, SUITE 4500, WALTHAM MA 02451
Karan S. Takhar	director	C/O ZENTALIS PHARMACEUTICALS,INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Antony C. Mattessich	director	C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730